Mehta A, Nathany S, Tripathi R, et al. - In human epidermal growth factor receptor 2 (HER2) gene mutated cases in non-small cell lung cancer (NSCLC), the incidence and spectrum of HER2 mutations, related clinicopathological features, and the co-occurrence of HER2 gene amplification were evaluated. Between 2015 and 2019, all individuals with advanced lung adenocarcinoma (LUAD) who had undergone broad genomic profiling by next-generation sequencing were included in the study. According to the findings, there is a relatively higher occurrence of HER2 exon 20 mutations as a primary oncogenic driver in NSCLC, particularly LUAD. The results revealed (p.E770_A771insAYVM) as the greatly dominant insertion mutation against the most often globally reported (p.A771_Y772insYVMA) in this cohort.